A 13-year-old Nashville boy has become the first commercial patient at TriStar Centennial Children's Hospital to receive a newly approved gene-editing treatment for sickle cell disease, following recent approval from the U.S. Food and Drug Administration.
The treatment is considered a potential cure for the blood disorder, which affects about 100,000 Americans, including approximately 3,500 people in Tennessee.